Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

VolitionRx reports positive interim results from Danish colorectal cancer study

Cameron Reynolds, chief executive of VolitionRx Ltd (NYSE:VNRX), discusses with Proactive's Andrew Scott the positive interim results from their trial in Denmark concerning colorectal cancer (CRC), which point to being able to detect early signs of the disease.

The ongoing study is in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program.

 
Meet Legend Mining Ltd, Nexus Minerals Ltd, Tyranna Resources Ltd, Global Health Ltd and Uscom Ltd at our event, Sydney , 23 July 2018. Register here »
View full VNRX profile View Profile

VolitionRx Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use